Skip to Content

View Additional Section Content

A Phase III, Open-Label, Randomized, Controlled Multi-Centre Study to Assess the Efficacy and Safety of Olaparib Monotherapy Versus Physician’s Choice Single Agent Chemotherapy in the Treatment of Platinum Sensitive Relapsed Ovarian Cancer in Patients Carrying Germline BRCA ½ Mutations

For more information on this trial, click the link below.

Principal Investigator(s)
Parviz Hanjani, M.D.

Clinical Trial Categories

  • Ovarian Cancer
Hanjani Institute for Gynecologic Oncology at 215-885-0220


  • Hanjani Institute for Gynecologic Oncology
    The Rosenfeld Cancer Center
    1200 Old York Rd, AMH - 1 Widener
    Abington, PA 19001
    Office: 215-885-0220
    Fax: 215-576-0740

Find a Physician
Search Our Directory


Schedule a


Clinical Trials Details